Previous clinical trials have demonstrated how TRIM21 reduces de novo lipogenesis and steatosis in hepatocytes by inhibiting FASN; this mechanism is detected in patients with TRIM21, which reduces hepatic de novo lipogenesis and steatosis in patients with obesity and MAFLD and obesity [67]. Here, TRIM21 is linked to Obesity.